Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. (WINT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
wint · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Windtree Therapeutics, Inc. (WINT) measures how much investors pay for each dollar of the company's trailing earnings. WINT's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$1499.64.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Windtree Therapeutics, Inc.You WINT | $0M | N/A | — | -$1499.64 |
 Ainos, Inc. AIMD | $9M | N/A | — | -$3.46 |
 Avenue Therapeutics, Inc. ATXI | $1M | N/A | — | -$0.93 |
 Dermata Therapeutics, Inc. DRMA | $1M | N/A | — | -$8.16 |
 PMGC Holdings Inc. ELAB | $3M | N/A | — | -$378.74 |
 GT Biopharma, Inc. GTBP | $5M | N/A | — | -$5.14 |
 NewcelX Ltd. NCEL | $1M | N/A | — | -$26.31 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-104.35 | — | |
2023-12-31 FY2023 | — | $-4712.26 | — | |
2022-12-31 FY2022 | — | $-56011.43 | — | |
2021-12-31 FY2021 | — | $-122924.88 | — | |
2020-12-31 FY2020 | — | $-87044.84 | — | |
2019-12-31 FY2019 | — | $-113138.27 | — | |
2018-12-31 FY2018 | — | $-616949.73 | — | |
2017-12-31 FY2017 | — | $-2422384.80 | — | |
2016-12-31 FY2016 | — | $-12815270.58 | — | |
2015-12-31 FY2015 | — | $-21380779.97 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Windtree Therapeutics, Inc. (WINT) measures how much investors pay for each dollar of the company's trailing earnings. WINT's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$1499.64.
Frequently asked questions
WINT pe ratio · 6 questionsWINT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of -$1499.64. Data sourced from Financial Modeling Prep via WINT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Windtree Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09